TY - JOUR
T1 - Randomized Trial of Rapid Multiplex Polymerase Chain Reaction-Based Blood Culture Identification and Susceptibility Testing
AU - Banerjee, Ritu
AU - Teng, Christine B.
AU - Cunningham, Scott A.
AU - Ihde, Sherry M.
AU - Steckelberg, James M.
AU - Moriarty, James P.
AU - Shah, Nilay D.
AU - Mandrekar, Jayawant N.
AU - Patel, Robin
N1 - Publisher Copyright:
© 2015 The Author.
PY - 2015/10/1
Y1 - 2015/10/1
N2 - Background.The value of rapid, panel-based molecular diagnostics for positive blood culture bottles (BCBs) has not been rigorously assessed. We performed a prospective randomized controlled trial evaluating outcomes associated with rapid multiplex PCR (rmPCR) detection of bacteria, fungi, and resistance genes directly from positive BCBs. Methods.A total of 617 patients with positive BCBs underwent stratified randomization into 3 arms: standard BCB processing (control, n = 207), rmPCR reported with templated comments (rmPCR, n = 198), or rmPCR reported with templated comments and real-time audit and feedback of antimicrobial orders by an antimicrobial stewardship team (rmPCR/AS, n = 212). The primary outcome was antimicrobial therapy duration. Secondary outcomes were time to antimicrobial de-escalation or escalation, length of stay (LOS), mortality, and cost. Results.Time from BCB Gram stain to microorganism identification was shorter in the intervention group (1.3 hours) vs control (22.3 hours) (P <. 001). Compared to the control group, both intervention groups had decreased broad-spectrum piperacillin-tazobactam (control 56 hours, rmPCR 44 hours, rmPCR/AS 45 hours; P =. 01) and increased narrow-spectrum β-lactam (control 42 hours, rmPCR 71 hours, rmPCR/AS 85 hours; P =. 04) use, and less treatment of contaminants (control 25%, rmPCR 11%, rmPCR/AS 8%; P =. 015). Time from Gram stain to appropriate antimicrobial de-escalation or escalation was shortest in the rmPCR/AS group (de-escalation: rmPCR/AS 21 hours, control 34 hours, rmPCR 38 hours, P <. 001; escalation: rmPCR/AS 5 hours, control 24 hours, rmPCR 6 hours, P =. 04). Groups did not differ in mortality, LOS, or cost. Conclusions.rmPCR reported with templated comments reduced treatment of contaminants and use of broad-spectrum antimicrobials. Addition of antimicrobial stewardship enhanced antimicrobial de-escalation. Clinical Trials Registration.NCT01898208.
AB - Background.The value of rapid, panel-based molecular diagnostics for positive blood culture bottles (BCBs) has not been rigorously assessed. We performed a prospective randomized controlled trial evaluating outcomes associated with rapid multiplex PCR (rmPCR) detection of bacteria, fungi, and resistance genes directly from positive BCBs. Methods.A total of 617 patients with positive BCBs underwent stratified randomization into 3 arms: standard BCB processing (control, n = 207), rmPCR reported with templated comments (rmPCR, n = 198), or rmPCR reported with templated comments and real-time audit and feedback of antimicrobial orders by an antimicrobial stewardship team (rmPCR/AS, n = 212). The primary outcome was antimicrobial therapy duration. Secondary outcomes were time to antimicrobial de-escalation or escalation, length of stay (LOS), mortality, and cost. Results.Time from BCB Gram stain to microorganism identification was shorter in the intervention group (1.3 hours) vs control (22.3 hours) (P <. 001). Compared to the control group, both intervention groups had decreased broad-spectrum piperacillin-tazobactam (control 56 hours, rmPCR 44 hours, rmPCR/AS 45 hours; P =. 01) and increased narrow-spectrum β-lactam (control 42 hours, rmPCR 71 hours, rmPCR/AS 85 hours; P =. 04) use, and less treatment of contaminants (control 25%, rmPCR 11%, rmPCR/AS 8%; P =. 015). Time from Gram stain to appropriate antimicrobial de-escalation or escalation was shortest in the rmPCR/AS group (de-escalation: rmPCR/AS 21 hours, control 34 hours, rmPCR 38 hours, P <. 001; escalation: rmPCR/AS 5 hours, control 24 hours, rmPCR 6 hours, P =. 04). Groups did not differ in mortality, LOS, or cost. Conclusions.rmPCR reported with templated comments reduced treatment of contaminants and use of broad-spectrum antimicrobials. Addition of antimicrobial stewardship enhanced antimicrobial de-escalation. Clinical Trials Registration.NCT01898208.
KW - PCR
KW - antimicrobial stewardship
KW - blood culture
KW - diagnostic
UR - http://www.scopus.com/inward/record.url?scp=84942084780&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84942084780&partnerID=8YFLogxK
U2 - 10.1093/cid/civ447
DO - 10.1093/cid/civ447
M3 - Article
C2 - 26197846
AN - SCOPUS:84942084780
SN - 1058-4838
VL - 61
SP - 1071
EP - 1080
JO - Clinical Infectious Diseases
JF - Clinical Infectious Diseases
IS - 7
ER -